{"disease":{"id":"waldenstrom-s-macroglobulinemia","name":"waldenstrom s macroglobulinemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02332980","title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT00422799","title":"Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT00697346","title":"Study of MLN8237 in Participants With Advanced Hematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03820817","title":"Rifaximin in Patients With Monoclonal Gammopathy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04440059","title":"A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00492050","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07420959","title":"ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03506373","title":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT05360238","title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT04274738","title":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"X4 Pharmaceuticals","has_results":false},{"nct_id":"NCT01198067","title":"Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03225716","title":"A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT01744912","title":"Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03269552","title":"Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT05645744","title":"Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.","phase":"","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT03679624","title":"Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT04635683","title":"Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Yazeed Sawalha","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}